How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19

by Ute Boronowsky | February 28, 2022


How a Global Network Accelerated the Development of a Virus-Like Particle Vaccine Against Covid-19

Setting up the logistics and cold chain infrastructure needed for vaccine deployment is expensive and cumbersome, contributing to low vaccination rates in African countries. Enabling local vaccine manufacturing in sufficient quantities and consistent quality could have a significant impact in fighting infectious diseases, including the Covid-19 pandemic.

A partnership between the biotech companies TechnoVax in the US, MilliporeSigma*, and Innovative Biotech in Nigeria aims to empower vaccine development in Africa. Innovative Biotech has developed vaccines against Ebola and HIV, and with the onset of the Covid-19 pandemic, the company quickly switched to the new target.

Learn More about this online article HERE. 

Register now for the free on-demand webinar HERE. 

* MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany

[starbox id=”UteBoronowsky”]

Ute Boronowsky obtained a PhD in plant biochemistry at the Ruhr-University Bochum in 1999. After her postdoc at UCLA, she moved to the biotech industry and worked in various sales and marketing positions. Since 2015, she works as a freelance science and marketing writer, translator, and journalist. LinkedIn:

Related Posts

Vaccine Maker’s Toolkit: Strategies For Manufacturing And Supply Management

This collection of insights, produced through a partnership between

Merck KGaA, Darmstadt, Germany
,[geot_filter region="north-america" country=""...


In this webinar, join industry experts to learn about strategies to accelerate mRNA therapies and enable scalability and...

Improved endotoxin removal using ecofriendly detergents for intensified plasmid capture

Purification efficiency evaluated endotoxin and host cell protein (HCP) clearance, plasmid yield, potential interference of the detergents with...

Watch on Demand! Biolabs European expansion

BioLabs builds innovation communities around Biotech entrepreneurs providing them with infrastructure, support, and networking to successfully succeed. Hear...

Mirrored disco balls

Bridging the Sponsor – CMO Data Gulf

Single-source manufacture of biopharmaceuticals is becoming more and more rare. Increasingly, biomanufacturers or “sponsor” companies partner with contract…

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

The covid-19 pandemic forced rapid vaccine development and market approval, shortening a process that normally takes years to...

Scroll to Top